HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $95 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $95 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $95 price target.